Small-cap healthcare has been left for dead, but the charts and earnings sentiment are beginning to turn.
June 16, 2026
Small-cap healthcare has been dead money for years.
While investors chased AI, crypto, megacap tech, space stocks, and other momentum plays, this corner of the market went nowhere.
The group peaked in early 2021, spent years digesting that prior bull market, and became one of the last places anyone wanted to look for leadership.
But that seems to be changing...
The Small-Cap Health Care ETF $PSCH, is now reclaiming its all-time high VWAP after carving out a multi-year bearish-to-bullish reversal pattern.
And that's a big deal because the last two times this ETF entered a sustained uptrend, the moves were massive.
One rally produced a 130% gain in 10 months.
The other produced a 138% gain in 11 months.
If history even comes close to rhyming, PSCH could be headed toward $90 by the first quarter of 2027.
And this is not just a biotech story...
When most people hear “small-cap healthcare,” they think tiny drug developers, FDA binary events, and speculative biotech charts.
But the actual makeup of PSCH is much more balanced.
Healthcare providers are the largest weighting at 27.7%, followed by biotechnology at 27.1%, healthcare equipment at 22%, and pharmaceuticals at 19.1%.
So when this group starts working, we want to look beyond the obvious biotech names and find the stocks where the technicals, fundamentals, and earnings sentiment are all starting to line up.
And that brings us to Molina Healthcare.
Molina is a $10.5 billion healthcare plan stock that provides managed healthcare services through Medicaid, Medicare, and state insurance marketplaces.
In plain English, this is a government-sponsored healthcare business.
It manages care for millions of members, takes capitated risk, and makes money when it can price that risk properly and manage medical costs better than the market expects.
And that hasn't been easy lately...
Medicaid redeterminations have created pressure, rates and medical costs have been out of balance, and investors have punished managed care stocks hard.
Molina has been no exception, falling from $360 last year to nearly $120 earlier this year.
But after an extended period of carving out a reversal pattern, MOH appears to be on the cusp of entering a brand-new primary uptrend.
If buyers can finally push MOH above $206, it could lead to a quick 40% upside move through a massive volume pocket.
And that's where things can get fun...
This is the zone where price collapsed last summer and left very little overhead volume behind.
If MOH breaks above the upper bound of this base, the stock could get sucked through that pocket quickly as supply dries up.
While the technicals are a thing of beauty, the earnings setup is just as compelling.
Heading into its latest report, Molina had been punished for five consecutive earnings events.
And these weren't small reactions either...
The stock fell 10%, 5.5%, 16.8%, 17.5%, and then 25.5% after February’s report, which produced a brutal negative reaction score of 9.22.
That is about as ugly as earnings sentiment gets.
But then something changed in April...
On April 22, Molina reported mixed headline results, missing revenue expectations but beating earnings estimates.
On the surface, the numbers weren't pretty.
Total revenue declined 3.2% YoY, and diluted EPS fell more than 61% YoY.
Normally, that's the kind of report a broken stock uses as an excuse to keep trending lower.
Instead, MOH rallied more than 14%, delivering its best earnings reaction in years and snapping the five-quarter beatdown streak.
That's exactly the kind of change in character we look for in reversals.
The market already knew the fundamentals were ugly.
It already knew the managed care space was under pressure.
And it already knew earnings had collapsed.
But when a stock rallies on mixed results and bad-looking YoY growth, the message is that the bad news may finally be priced in.
The follow-through has been just as important.
For the first time since October 2023, Molina posted positive pre- and post-earnings drift.
Since the report, the stock has continued to grind higher, rising roughly 19% as investors accumulated shares after the event rather than selling into the strength.
The fundamentals aren't yet in an uptrend, but management has laid out a path for improvement.
Earnings sentiment just flipped from a major headwind to a potential tailwind.
And the chart is pressing against a significant breakout level with a massive volume pocket sitting directly overhead.
If MOH clears $206 and holds above that level, the path of least resistance will shift decisively higher, with the $206-$286 volume pocket acting like a vacuum.
And when a formerly hated healthcare stock starts acting well at the same time small-cap healthcare is breaking out, it sets the stage for a BIG move.
Setups like this are exactly why we built the Premium Beat Report.
In the free Daily Beat, we show you the biggest earnings reactions, plus the technical and fundamental stories behind them.
But in the Premium Beat Report, we turn our best ideas into actionable trade alerts.
And we've already started putting money to work in small-cap healthcare.
On Monday, we bought calls on one of our favorite names in the group because we think it could multiply our money from here.
When the next trade triggers, Premium Beat Report members will hear about it first.
Editor's Note: More than a trillion dollars in new equity is about to hit the public markets, and Steve thinks most traders are about to be standing on the wrong side of it.
He's hosting a FREE live training tomorrow at 4:30 pm ET to show you where that money is actually headed.
